ALKS : Analysis & Opinions

  1. Alkermes Starts Phase I Study on Schizophrenia Candidate - Analyst ...

    December 16, 2014
    Alkermes (ALKS) announced the commencement of a phase I extended dosing study on aripiprazole lauroxil for the treatment ...
  2. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  3. Elan Hives Off Prothena - Analyst Blog

    December 27, 2012
    Elan Corporation, plc (ELN), a neuroscience-based biotechnology company, recently completed the separation of a significant ...
  4. Profit Locally, Invest Globally

    June 30, 2008
    As the U.S. equity market drops, overseas stocks appear more and more attractive. We examine a trio of ADRs ready to grow. ...
  5. Medicine's Marketing Machines (CEPH, FRX, SHPGY)

    September 13, 2007
    We examine three pharmaceutical companies known as much for their ads as they are for their treatments.
Trading Center